Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immatics ( (IMTX) ) has shared an announcement.
On October 27, 2025, Immatics N.V. announced the appointment of Amie Krause as Chief People Officer, effective immediately. With over 20 years of experience in organizational growth and talent alignment in the biopharmaceutical sector, Krause will lead the company’s human resources as it transitions to a commercial-stage enterprise. Her role is pivotal as Immatics prepares for the commercialization of its lead PRAME cell therapy candidate, anzu-cel, aiming to enhance its global leadership in precision targeting of PRAME and improve cancer treatment options.
The most recent analyst rating on (IMTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Immatics stock, see the IMTX Stock Forecast page.
Spark’s Take on IMTX Stock
According to Spark, TipRanks’ AI Analyst, IMTX is a Neutral.
The overall stock score of 55 reflects a mixed outlook for Immatics. The most significant factor is the company’s financial performance, which is challenged by declining revenues and profitability issues. However, technical analysis indicates a bullish trend, providing some positive momentum. Valuation remains a concern due to negative earnings and lack of dividends, which weigh down the overall score.
To see Spark’s full report on IMTX stock, click here.
More about Immatics
Immatics N.V. is a clinical-stage biopharmaceutical company specializing in precision targeting of PRAME, a target expressed in over 50 types of cancer. The company is a leader in developing TCR T-cell therapies and TCR bispecifics, with a robust clinical pipeline aimed at providing innovative cancer treatments.
Average Trading Volume: 860,627
Technical Sentiment Signal: Buy
Current Market Cap: $1.24B
Find detailed analytics on IMTX stock on TipRanks’ Stock Analysis page.